电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

ETV5 抗体 (AA 8-36)

ETV5 适用: 人 WB, ELISA, FACS 宿主: 兔 Polyclonal unconjugated
产品编号 ABIN3030878
发货至: 中国
  • 抗原 See all ETV5 抗体
    ETV5 (Ets Variant 5 (ETV5))
    抗原表位
    • 16
    • 15
    • 12
    • 7
    • 6
    • 4
    • 2
    • 1
    • 1
    AA 8-36
    适用
    • 65
    • 29
    • 8
    • 6
    • 5
    • 5
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    宿主
    • 53
    • 12
    克隆类型
    • 54
    • 11
    多克隆
    标记
    • 23
    • 7
    • 6
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    This ETV5 antibody is un-conjugated
    应用范围
    • 55
    • 33
    • 13
    • 13
    • 13
    • 6
    • 5
    • 4
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Flow Cytometry (FACS)
    纯化方法
    Antigen affinity purified
    免疫原
    A portion of amino acids 8-36 from the human protein was used as the immunogen for this ETV5 antibody.
    亚型
    Ig Fraction
    Top Product
    Discover our top product ETV5 Primary Antibody
  • 应用备注
    Titration of the ETV5 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,Flow Cytometry: 1:10-1:50
    限制
    仅限研究用
  • 状态
    Liquid
    缓冲液
    In 1X PBS, pH 7.4, with 0.09 % sodium azide
    储存液
    Sodium azide
    注意事项
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    储存条件
    -20 °C
    储存方法
    Aliquot the ETV5 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
  • 抗原
    ETV5 (Ets Variant 5 (ETV5))
    别名
    ETV5 (ETV5 产品)
    别名
    ERM antibody, etv5 antibody, fj87h10 antibody, id:ibd5133 antibody, wu:fj87h10 antibody, zgc:55647 antibody, 1110005E01Rik antibody, 8430401F14Rik antibody, ETS variant 5 antibody, ets variant 5 antibody, ets variant 5a antibody, ETV5 antibody, Etv5 antibody, etv5a antibody
    背景
    The ETS family of transcription factors, characterized by an evolutionarily conserved DNA-binding domain, regulates expression of more than 300 target genes by binding to a purine-rich GGAA/T core sequence. Depending on the cellular context, they can function as transactivators or transrepressors. Ets proteins have been implicated in regulation of gene expression during a variety of biological processes, including growth control, transformation, T-cell activation, and developmental programs in many organisms. Signals regulating cell growth are transmitted from outside the cell to the nucleus by growth factors and their receptors, G-proteins, kinases and transcription factors. It was shown that ETS signal transduction is implicated in hematopoiesis and angiogenesis at the earliest stages of embryogenesis, and is later involved in tissue development. Deregulated expression and/or formation of chimeric fusion proteins of the ETS family due to proviral insertion or chromosome translocation is associated with leukemias and with specific types of solid tumors.1 Among the multiple Ets proteins, the PEA3 group consists of ETV1 (Ets variant gene 1, also called ER81), ETV4 (also called PEA3) and ETV5 (also called ERM). All three members are 95 % identical in the ETS domain and more than 85 % in the acidic transactivation domain. Several studies suggest that the PEA3 group proteins are involved in intestinal tumors, gastric cancer, and breast cancer metastasis. In nearly all Ewing?s sarcoma tumors, EWS, which encodes a RNA-binding protein, is fused by chromosomal translocation to an Ets gene, including FLI, ERG, ETV4, and ETV1. This results in the expression of chimeric proteins that may be important in tumor cell transformation.2 Recently, it was reported that TMPRSS2, an AR-regulated gene, is fused by translocation to the ETV1, ERG, or ETV4 gene in a subset of prostate cancers. These findings suggest an important role for PEA3 proteins in prostate cancer.3 In addition Ets family members have been correlated to tumor progression by upregulating the expression of matrix-degrading proteases. The acquisition of a migratory phenotype by the epithelial tumor cells together with the remodeling of the extracellular matrix must accompany the process of cancer cell invasion. Indeed, ETV5 has been shown to act through matrix metalloproteinase-2 gelatinolytic activity to confer invasive capabilities, associated with an initial switch to myometrial infiltration.4
    UniProt
    P41161
    途径
    Synaptic Membrane, Skeletal Muscle Fiber Development
You are here:
客服